Axial Spondyloarthritis (axSpA) - Pipeline Insight, 2025: Novel Biologics and JAK Inhibitors Offer Hope for Personalized, Inflammation-Controlled Care | DelveInsight

Axial spondyloarthritis (axSpA), a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, severely impairs mobility and quality of life. While TNF and IL-17 inhibitors have revolutionized treatment, a significant proportion of patients remain inadequately managed, necessitating new therapeutic strategies.

As of 2025, the axSpA pipeline features over 12 innovative assets, including IL-23 inhibitors, JAK inhibitors, TYK2 modulators, and biospecific antibodies. Leading companies such as Galapagos NV, Jiangsu Hengrui Pharmaceutical Co., Ltd., Akeso, Inc., Izana Bioscience Ltd., and Biocad are spearheading efforts to improve disease control and delay structural damage with more personalized and targeted options.

DelveInsight's "Axial Spondyloarthritis - Pipeline Insight, 2025" evaluates the evolving treatment landscape, covering late-stage trials, MoA differentiation, biomarker-driven drug development, and expanding treatment opportunities for non-radiographic axSpA populations.

As the therapeutic focus shifts toward individualized inflammation management and early intervention, the axSpA pipeline is primed to deliver more durable and tolerable treatment options for long-term disease control.

Interested in learning more about the current treatment landscape and the key drivers shaping the axial spondyloarthritis pipeline? Click here: https://www.delveinsight.com/report-store/axial-spondyloarthritis-axspa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Axial Spondyloarthritis Pipeline Report
• DelveInsight's axial spondyloarthritis pipeline analysis depicts a strong space with 10+ active players working to develop 12+ pipeline drugs for axial spondyloarthritis treatment.
• The leading axial spondyloarthritis companies include Galapagos NV, Jiangsu Hengrui Pharmaceutical Co., Ltd., Akeso, Inc., Izana Bioscience Ltd., Biocad, Mabpharm Limited, Shilpa Biologicals and others are evaluating their lead assets to improve the axial spondyloarthritis treatment landscape.
• Key axial spondyloarthritis pipeline therapies in various stages of development include Filgotinib, SHR0302, AK111, Namilumab, BCD-180, CMAB015, SBDM-002, and others.
• In September 2024, UCB announced that the FDA had approved BIMZELX (bimekizumab-bkzx) for adults with active psoriatic arthritis, active non-radiographic axial spondyloarthritis with objective signs of inflammation, and active ankylosing spondylitis. This makes BIMZELX the first and only IL-17A and IL-17F inhibitor approved in the U.S. for these four chronic immune-mediated inflammatory diseases.

Request a sample and discover the recent breakthroughs happening in the axial spondyloarthritis pipeline landscape at https://www.delveinsight.com/report-store/axial-spondyloarthritis-axspa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Axial Spondyloarthritis Overview
Axial Spondyloarthritis (axSpA) is a chronic inflammatory disease that primarily affects the spine and sacroiliac joints, leading to persistent back pain and stiffness. It typically begins before the age of 45 and can significantly impair mobility and quality of life if left untreated. The condition is classified into two forms: radiographic axSpA (also known as ankylosing spondylitis) and non-radiographic axSpA, depending on whether structural changes are visible on X-rays.

The disease is strongly associated with the HLA-B27 gene and can present with symptoms such as morning stiffness, fatigue, and peripheral joint involvement. Extra-articular manifestations like uveitis or inflammatory bowel disease may also occur. Diagnosis involves clinical evaluation, imaging (MRI or X-ray), and inflammatory markers. Treatment usually includes NSAIDs, physical therapy, and biologics like TNF or IL-17 inhibitors to control inflammation, improve function, and prevent structural damage.

Find out more about axial spondyloarthritis medication at https://www.delveinsight.com/report-store/axial-spondyloarthritis-axspa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Axial Spondyloarthritis Treatment Analysis: Drug Profile
Filgotinib: Galapagos NV
Filgotinib, marketed as Jyseleca in Europe and Japan, is approved for the treatment of moderate to severe active rheumatoid arthritis (RA) and ulcerative colitis (UC) in adult patients who have had an inadequate response or intolerance to conventional therapies or biologics. It is a once-daily, orally administered, JAK1-selective inhibitor. Currently, Filgotinib is being investigated in a Phase III trial for axial spondyloarthritis (AxSpA), expanding its potential indications in autoimmune and inflammatory diseases.

SCT650C: Sinocelltech
SCT650C is a novel humanized monoclonal antibody targeting interleukin-17A (IL-17A), a key cytokine involved in the pathogenesis of autoimmune conditions such as ankylosing spondylitis. Developed by Sinocelltech, the drug is currently undergoing evaluation in a Phase II clinical trial for the treatment of ankylosing spondylitis, aiming to offer a new therapeutic option in the IL-17A inhibition space.

Learn more about the novel and emerging axial spondyloarthritis pipeline therapies at https://www.delveinsight.com/report-store/axial-spondyloarthritis-axspa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Axial Spondyloarthritis Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

By Molecule Type
• Oligonucleotide
• Peptide
• Small molecule

Scope of the Axial Spondyloarthritis Pipeline Report
• Coverage: Global
• Key Axial Spondyloarthritis Companies: Galapagos NV, Jiangsu Hengrui Pharmaceutical Co., Ltd., Akeso, Inc., Izana Bioscience Ltd., Biocad, Mabpharm Limited, Shilpa Biologicals, and others.
• Key Axial Spondyloarthritis Pipeline Therapies: Filgotinib, SHR0302, AK111, Namilumab, BCD-180, CMAB015, SBDM-002, and others.

Dive deep into rich insights for drugs used for Axial Spondyloarthritis treatment, visit: https://www.delveinsight.com/report-store/axial-spondyloarthritis-axspa-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Axial Spondyloarthritis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Axial Spondyloarthritis Pipeline Therapeutics
6. Axial Spondyloarthritis Pipeline: Late-Stage Products (Phase III)
7. Axial Spondyloarthritis Pipeline: Mid-Stage Products (Phase II)
8. Axial Spondyloarthritis Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.